New patent for Sanofi Aventis drug APIDRA SOLOSTAR

Annual Drug Patent Expirations for APIDRA+SOLOSTAR
Annual Drug Patent Expirations for APIDRA+SOLOSTAR

Apidra Solostar is a drug marketed by Sanofi Aventis Us
and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug.

This drug has two hundred and three patent family members in forty-two countries.

The generic ingredient in APIDRA SOLOSTAR is insulin glulisine recombinant. One supplier is listed for this compound. Additional details are available on the insulin glulisine recombinant profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com